01—Abstract
Summary
Summary of the 8-K filed January 9, 2023. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. filed an 8-K on January 9, 2023, providing preliminary unaudited financial results for the fiscal year ended December 31, 2022.
The company announced robust product sales of approximately $18.4 billiona, primarily driven by its COVID-19 vaccine. This strong revenue performance is a key takeaway for investors, demonstrating the continued commercial success of Moderna's flagship product. In addition to significant sales, Moderna reported research and development expenses of approximately $3.3 billion, highlighting its ongoing commitment to innovation and pipeline development.
The company also ended the year with a strong liquidity position, expecting over $18 billionb in cash, cash equivalents, and marketable securities. Investors should note that these figures are preliminary and unaudited, with final audited results to be released later.
02—Key points
Key Highlights
- Preliminary product sales for FY 2022 reached approximately $18.4 billion, driven by COVID-19 vaccine sales.
- Research and development expenses for FY 2022 were approximately $3.3 billion.
- Moderna expects to have over $18 billion in cash, cash equivalents, and marketable securities as of December 31, 2022.
- The preliminary financial information was shared during the 41st Annual J.P. Morgan Healthcare Conference.
- The reported figures are unaudited and preliminary; final audited results may differ.
03—Questions
Frequently Asked Questions
What were Moderna's key financial results for the fiscal year 2022?
Moderna reported preliminary unaudited product sales of approximately $18.4 billion for the fiscal year 2022, driven by its COVID-19 vaccine. The company also incurred approximately $3.3 billion in research and development expenses and anticipates having over $18 billion in cash, cash equivalents, and marketable securities as of December 31, 2022.
Are these financial figures audited?
No, the financial information provided in this 8-K filing is preliminary and unaudited. The audit of the company's financial statements for the fiscal year ended December 31, 2022, is ongoing, and the final audited results may differ from these preliminary figures.
What is the significance of the $18.4 billion in product sales?
The $18.4 billion in product sales represents the total revenue generated primarily from Moderna's COVID-19 vaccine for the fiscal year 2022. This figure indicates the significant commercial success and market demand for the company's vaccine during the reporting period.
Why did Moderna release this information in an 8-K filing?
Moderna released this information in an 8-K filing to disclose preliminary financial results and business updates in connection with its presentation at the 41st Annual J.P. Morgan Healthcare Conference. This allows the company to share material information with investors in a timely manner.
04—Continue